- PROFESSOR AND SYSTEM CHAIR Psychiatry
- PROFESSOR Neuroscience
Psychiatry, American Board of Psychiatry and Neurology
MD, Boston University
Hospital of St. Raphael
Yale-New Haven Psychiatric Hospital
Yale School of Medicine
- On July 1, 2009, Dr. Goodman was appointed Professor and Chairman of the Department of Psychiatry at the Mount Sinai School of Medicine in New York City. He is the Esther and Joseph Klingenstein Professor of Psychiatry and Professor in the Department of Neuroscience.
Prior to joining Mt. Sinai, he served as Director, Division of Adult Translational Research and Treatment Development (DATR), at the National Institute of Mental Health in Bethesda, Maryland from 2007-2009. He has conducted pioneering research in the field of Obsessive-Compulsive Disorder (OCD) and is the principal developer of the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), the gold standard for assessing OCD. He is co-founder of the Obsessive Compulsive Foundation, the national patient advocacy organization for this disorder.
Dr. Goodman is a native of New York City and attended the Bronx High School of Science. A graduate of Columbia University with a BS in electrical engineering, Dr. Goodman received his medical degree from Boston University and completed his internship, residency, and a research fellowship at Yale University School of Medicine where he remained on faculty until 1993 as an Associate Professor. In 1994, he joined the University of Florida in Gainesville where he served as Chairman of the Department of Psychiatry for nine years. Dr. Goodman has published more than 250 articles in scientific journals and has been principal investigator on NIMH-funded grants since 1992. He is a member of the American College of Neuropsychopharmacology and a Distinguished Fellow of the American Psychiatric Association. He is the 2010 recipient of the Mysell Lecture Award from Harvard University and in 2012 he received the Lifetime Career Achievement Award from International OCD Foundation.
As Chair of Psychiatry, Dr. Goodman works closely with the new Mount Sinai Brain Institute to conduct research on neuropsychiatric disorders such as schizophrenia, Alzheimer's disease, and mood disorders. Dr. Goodman is an expert psycho-pharmacologist who previously served as Chair of the Food and Drug Administration's (FDA's) Psychopharmacologic Drug Advisory Committee.
Optimizing Care Today and Developing the Treatments of Tomorrow at Mount Sinai
In the News
Dr. Goodman discusses OCD in The Daily News feature The Daily Check Up.
View the PDF.
Financial & Billing Information
Please direct any detailed billing or financial inquires to the Mount Sinai Psychiatry billing customer service number at 212-659-8752.
ResearchMy primary areas of research interest are obsessive compulsive disorder (OCD) and related disorders such as Tourette's Syndrome (TS) in children and adults. I am interested in advancing the treatment of OCD through a better understanding of its pathophysiology. During a span of 20 years, I have investigated the phenomenology, neurobiology and treatment of OCD. In recent years, I have focused on developing approaches to treatment-resistant OCD including the study of Deep Brain Stimulation (DBS).
Goodman WK, Insel TR. Deep brain stimulation in psychiatry: concentrating on the road ahead. Biol Psychiatry 2009 Feb 15; 65(4): 263-266.
Goodman WK, Murphy TK, Storch EA. Risk of adverse behavioral effects with pediatric use of antidepressants. Psychopharmacology 2007; 191: 87-96.
Okun MS, Mann G, Foote KD, Shapira NA, Bowers D, Springer U, Knight W, Martin P, Goodman WK. Internal Capsule and Nucleus Accumbens Region DBS: Responses Observed During Active and Sham Programming. J Neurol Neurosurg Psychiatry 2007; 78(3): 310-314.
Shapira NA, Ward HE, Mandoki M, Murphy TK, Yang MC, Blier P, Goodman WK. A double-blind placebo controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry 2004; 55(5): 553-555.
Murphy TK, Sajid M, Soto O, Shapira N, Edge PJ, Yang M, Lewis M, Goodman WK. Detecting pediatric autoimmune neuropsychiatric disorders associated with strepto-coccus (PANDAS) in children with OCD and tics. Biol Psychiatry 2004; 55: 61-68.
Shapira NA, Liu Y, He AG, Bradley MM, Lessig MC, James GA, Stein DJ, Lang PJ, Goodman WK. Brain activation by disgust-inducing pictures in obsessive-compulsive disorder. Biol Psychiatry 2003; 54: 751-756.
McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psych 1994; 51: 302-308.
Goodman WK, Price LH, Delgado PL, Palumbo J, Krystal JH, Nagy LM, Rasmussen SA, Heninger GR, Charney DS. Specificity of serotonin reuptake inhibitors in the treatment of obsessive- compulsive disorder: Comparison of fluvoxamine and desipramine. Arch Gen Psych 1990; 47: 577-585.
Goodman WK, Price LM, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS): Part I. Development, use, and reliability. Arch Gen Psych 1989; 46: 1006-1011.
Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney DS. Efficacy of fluvoxamine in obsessive-compulsive disorder: A double-blind comparison with placebo. Arch Gen Psych 1989; 46: 36-44.
- Reclaim Deep Brain Stimulation Therapy for Obsessive-Compulsive Disorder
- A Clinical Pilot Study Examining Bilateral Inhibition of the Lateral Habenula as a Target for Deep Brain Stimulation in Intractable Depression
- A Phase II, Multi-Center, Randomized, Double-Blind, Parallel-Group Placebo-Controlled Study to Evaluate Efficacy and Safety of RO4917838 in Combination with Selective Serotonin Reuptake Inhibitors in Patients with Obsessive Compulsive Disorder
- A Prospective, Double Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of the Deep Transcranial Magnetic Stimulation (DTMS) for the treatment of Obsessive Compulsive Disorder
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Goodman during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.
- Medtronic, Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
One Gustave L Levy Place
New York, NY 10029
New York, NY 10029
- Master Card
- American Express
- Personal Check
- Credit Card (Other)